Climb Bio (CLYM) Oppenheimer 36th Annual Healthcare Life Sciences Conference summary

Strategic focus and pipeline overview

• Focus on developing differentiated monoclonal antibody therapeutics for immune-mediated diseases, targeting clinically validated pathways such as CD19 and APRIL.

• Pipeline includes budoprutug (anti-CD19) and CLYM116 (anti-APRIL), both acquired externally and positioned for overlooked opportunities.

• Budoprutug targets B-cell and autoantibody-driven diseases, with a lead indication in primary membranous nephropathy (PMN), and additional programs in ITP and lupus.

• CLYM116 is a novel sweeper antibody targeting APRIL, aiming for improved potency and dosing convenience in IgA nephropathy (IgAN).

• Subcutaneous formulations are in development to enhance patient and provider flexibility.

Clinical development and data readouts

• Phase 1B data for budoprutug in PMN showed profound B-cell depletion and durable remissions, with 60% of patients achieving complete remission up to three years off treatment.

• Ongoing phase 2 study in PMN is enrolling, with initial data on B-cell depletion, immunologic response, and proteinuria expected by year-end.

• Subcutaneous budoprutug phase 1 healthy volunteer data expected in the first half of the year; CLYM116 healthy volunteer data mid-year.

• Initial data from budoprutug in ITP, SLE, and PMN anticipated in the second half of the year.

• Preclinical studies of CLYM116 showed superior IgA reduction and longer half-life compared to Sibeprenlimab, supporting potential for less frequent dosing.

Market positioning and competitive landscape

• Budoprutug is differentiated from existing CD19 therapies (e.g., UPLIZNA) by offering a subcutaneous option and leveraging learnings to accelerate pivotal trials.

• Antibody approach seen as safer and more broadly applicable than cell therapies like CAR-T, which are reserved for severe cases.

• CLYM116 aims to address efficacy, convenience, and safety gaps in the evolving IgAN treatment landscape, with a focus on monotherapy but openness to future combinations.

• The company is positioned to independently advance pivotal trials in core indications, with potential for partnerships in broader or more complex indications.

• Financial runway extends into 2028, with flexibility to raise additional funds for pivotal trials and expanded indications.